| | | | 一、审计报告…………………………………………………………第 | 1—6 | | 页 | | --- | --- | --- | --- | | 二、财务报表……………………………………………………… 第 | 7—14 | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 7 | 页 | | （二）母公司资产负债表………………………………………… | 第 | 8 | 页 | | （三）合并利润表………………………………………………… | 第 | 9 | 页 | | （四）母公司利润表………………………………………………第 | | 10 | 页 | | （五）合并现金流量表……………………………………………第 | | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | | 14 | 页 | | 三、财务报表附注…………………………………………………第 | 15 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 （三）执业会计师资格证书复印件………………………… 第 9—10 页 （一）本所营业执照复印件……………………………………… 第 7 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—6 页 三、附件…………………………………………………………… 第 7—10 页 （二）本所执业证书复印件……………………………………… 第 8 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 二、管理层的责任 大博医疗公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号——业务 办理（2024 年修订）》（深证上〔2024〕397 号）的规定编制汇总表，并保证其 内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 10 页 三、注册会计师的责任 天健审〔2025〕6933 号 大博医疗科技股份 ...

目 录 | 一、内部控制审计报告…………………………………………第 | 1—2 | | 页 | | --- | --- | --- | --- | | 二、附件…………………………………………………………第 | 3—6 | | 页 | | （一）本所营业执照复印件……………………………………… | 第 | 3 | 页 | | （二）本所执业证书复印件……………………………………… | 第 | 4 | 页 | | （三）执业会计师资格证书复印件………………………… 第 | 5—6 | | 页 | 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是大博 医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 天健审〔2025〕6931 号 大博医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了大博医疗科技股份有限 ...

中信证券股份有限公司 关于大博医疗科技股份有限公司 2024 年度募集资金年度存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为大博医 疗科技股份公司（以下简称"大博医疗"或"公司"）2020 年度非公开发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法（2023 年修订）》《深 圳证券交易所股票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》和《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》 等文件的相关要求，对大博医疗 2024 年度募集资金年度存放与使用的相关情况 进行了核查，具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据《上市公司自律监管指引第 1 号——主板上市公司规范运作》相关规 定，节余资金（包括利息收入）低于五百万元或者低于项目募集资金净额 1%的， 可以豁免董事会、股东大会等审议程序，其使用情况应当在年度报告中披露。本 次募集资金专户所存放的募集资金已按规定用途使用完毕。为规范募集资金 ...

Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, with no bonus shares issued[5] - A cash dividend of CNY 2.5 per 10 shares was distributed, totaling approximately CNY 1.04 billion, which is 175.51% of the net profit for 2023[57] - The company plans to distribute a cash dividend of CNY 5 per 10 shares for the 2024 fiscal year, totaling around CNY 2.03 billion[57] - The total cash dividend, including other methods such as share buybacks, amounted to 438,236,334.87 CNY, representing 100% of the total distributable profit of 1,529,141,179.64 CNY[166] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the last fiscal year[15] - The company's operating revenue for 2024 reached ¥2,135,559,372.81, representing a 39.29% increase compared to ¥1,533,121,281.80 in 2023[21] - Net profit attributable to shareholders for 2024 was ¥356,803,430.03, a significant increase of 505.16% from ¥58,972,461.01 in 2023[21] - The net profit after deducting non-recurring gains and losses was ¥285,403,513.61, reflecting a 2,603.93% increase from ¥10,555,124.81 in 2023[21] - The net cash flow from operating activities for 2024 was ¥442,300,420.61, up 498.58% from ¥73,861,966.30 in 2023[21] - Basic and diluted earnings per share for 2024 were both ¥0.86, marking a 514.29% increase from ¥0.14 in 2023[21] - The gross profit margin for the reporting period was 68.75%[54] Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in Southeast Asia, aiming for a 20% increase in market share by 2025[15] - New product development is underway, with three innovative medical devices expected to launch in Q3 2025, projected to contribute an additional 10% to annual revenue[15] - The company has successfully completed two strategic acquisitions in the past year, enhancing its product portfolio and distribution capabilities[15] - The company plans to leverage national policy directions and market trends to enhance its competitive capabilities and capitalize on procurement opportunities[34] - The company is committed to increasing its market share in artificial joint products, which are the fastest-growing segment in the orthopedic implant market[103] Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for the upcoming fiscal year, targeting advancements in minimally invasive surgical technologies[15] - Research and development investment reached ¥306,869,754.43 in 2024, an increase of 7.57% from ¥285,275,500.97 in 2023, representing 14.37% of total operating revenue[79] - The number of R&D personnel increased by 10.45% to 835 in 2024, while the proportion of R&D personnel to total staff slightly decreased to 18.54%[79] - The company has a complete and independent research and development system, with the ability to operate independently in the market[128] Risk Management - The company has identified key risks for future growth, including regulatory changes and supply chain disruptions, and has outlined mitigation strategies[5] - The company faces risks from industry policy changes, foreign business operations, and product development, and will adjust its strategies accordingly[108][109] Corporate Governance - The company has established a "Quality and Return Improvement" action plan to enhance corporate governance and investor communication[114] - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[119] - The board of directors consists of 7 members, including 3 independent directors, complying with the requirements of the China Securities Regulatory Commission[121] - The company has established various internal systems for information disclosure, ensuring compliance with relevant laws and regulations[126] Environmental Responsibility - The company is committed to environmental protection and sustainable development, advocating for resource conservation and low pollution practices in its operations[195] - The company has implemented measures to ensure that all emissions are within the required standards, with no exceedances reported[188] - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[189] Employee Management - The company has a competitive salary policy, ensuring that at least 20% of the distributable profits are allocated for cash dividends if conditions are met[161] - The company has implemented a stock option incentive plan to enhance employee motivation and align interests with shareholders[158] - The company has a structured training program aimed at developing talent and ensuring a smooth integration of new employees[159] Shareholder Relations - The company emphasizes the importance of intellectual property rights, which are crucial for maintaining competitive advantage in the orthopedic medical device market[110] - The company is committed to improving information disclosure quality and strengthening investor relations to promote long-term sustainable development[116] - The company has accumulated cash dividends of approximately 311 million yuan from 2021 to 2023, accounting for about 37.66% of the net profit attributable to shareholders during the same period[115]

A股创新药板块上扬，润都股份、江苏吴中涨停，健友股份涨超6%，康辰药业、贝达药业等跟涨。 ...

大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗68.26232.804.34137.29亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.24 ...

Core Viewpoint - The orthopedic implant medical device market in China is experiencing continuous growth, driven by an aging population, increased traffic accidents, and a rising demand for quality health care. The market size has expanded from 36.7 billion RMB in 2020 to 54.8 billion RMB in 2023, with projections to reach 59.2 billion RMB in 2024 [1][10]. Industry Definition and Classification - Orthopedic implant medical devices are surgical instruments implanted in the human body to replace, support, fix, or enhance bone, joint, and spinal tissues, aimed at restoring or improving bone function, promoting healing, alleviating pain, and enhancing the quality of life [2]. Industry Chain Analysis - The industry chain includes upstream raw material supply, midstream manufacturing, and downstream consumer demand. Upstream materials include metals, inorganic non-metals, polymers, and carbon materials, with a gradual increase in domestic supply. Midstream companies manufacture various orthopedic implants, while downstream distributors deliver products to medical institutions [4]. Industry Development History - The development of the orthopedic implant medical device industry in China can be divided into four stages: the embryonic period (early 20th century), the initial period (post-1949 to mid-1980s), the rapid development period (mid-1980s to early 21st century), and the market expansion and import substitution period (early 21st century to present) [6]. Current Industry Development Status - By the end of 2024, the population aged 65 and above in China is expected to reach 220 million, marking a significant increase in demand for orthopedic implants, particularly in the spinal and joint implant sectors [8][10]. Market Segmentation - The market segmentation shows that trauma products account for 38%, joint products 32%, spinal products 23%, and sports medicine products 5%. The trauma segment benefits from widespread applications in treating common orthopedic conditions, while the joint segment is driven by the aging population and increasing joint disease prevalence [12]. Key Companies Analysis - The competitive landscape features several key players: - Weigao Orthopedics offers a wide range of products across various orthopedic fields and emphasizes innovation [14]. - Spring Medical focuses on joint products and is expanding its business [14]. - Dabo Medical excels in trauma products and is venturing into other areas [14]. - Sanyou Medical specializes in spinal products and is extending its product line [14]. - Kelly Tai is focused on minimally invasive spinal products [14]. - Aikang Medical is known for its innovations in joint products [14]. Future Development Trends - The industry is expected to see accelerated import substitution, with domestic companies closing the technology gap with foreign brands and gaining market share due to cost advantages and better local service [19]. - Product innovation is increasing, driven by advancements in clinical medicine and materials science, leading to the development of smaller, more precise implants and the use of new materials [20][21]. - Research on bioactive materials is gaining momentum, with a focus on materials that promote bone growth and healing, enhancing the performance and stability of orthopedic implants [22].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Dabo Medical (002901), indicating a positive trend in stock price and significant inflow of funds from institutional and retail investors [1][2] - As of April 14, 2025, Dabo Medical's stock closed at 34.68 yuan, reflecting a 2.15% increase, with a trading volume of 21,000 hands and a total transaction amount of 73.0651 million yuan [1] - The net inflow of funds on April 14, 2025, was 372.74 thousand yuan from institutional investors, accounting for 5.1% of the total transaction amount, while retail investors experienced a net outflow of 904.27 thousand yuan, representing 12.38% of the total [1] Group 2 - Dabo Medical's total market capitalization is 14.358 billion yuan, which is higher than the industry average of 10.282 billion yuan, ranking 16th out of 121 in the medical device industry [2] - The company's net profit for the third quarter of 2024 was 240 million yuan, showing a year-on-year increase of 145.48%, with a significant rise in quarterly revenue to 565 million yuan, up 50.38% year-on-year [2] - Dabo Medical's gross profit margin stands at 68.47%, significantly above the industry average of 52.99%, indicating strong profitability compared to its peers [2]

Group 1 - The core viewpoint of the article highlights that Dabo Medical's stock closed at 33.75 yuan, with a 2.43% increase, and a rolling PE ratio of 69.47 times, resulting in a total market capitalization of 13.973 billion yuan [1] - Dabo Medical ranks 103rd in the medical device industry, which has an average PE ratio of 46.15 times and a median of 29.13 times [1] - As of the Q3 2024 report, 142 institutions hold shares in Dabo Medical, with a total of 13.8455 million shares valued at 427 million yuan [1] Group 2 - Dabo Medical's main business involves the production, research, and sales of high-value medical consumables, including orthopedic trauma implants, spinal implants, joint implants, sports medicine and neurosurgery implants, minimally invasive surgical consumables, and dental implants [1] - The latest performance report for Q3 2024 shows that the company achieved an operating income of 1.529 billion yuan, a year-on-year increase of 35.88%, and a net profit of 240 million yuan, a year-on-year increase of 145.48%, with a gross profit margin of 68.47% [1]